There are a number of companies, including Aspen, advancing cell therapies for Parkinson’s disease.

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety with preliminary assessments of visual and retinal functional outcomes.

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma Eligible ...

Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...

Bayer’s BAYRY wholly owned subsidiary, BlueRock Therapeutics, announced that the first patient in the phase I/IIa CLARICO study has received OpCT-001, an investigational iPSC-derived cell therapy, ...

Between April 4, 2023, and December 26, 2024, 43 patients were screened, 40 were enrolled, and 36 received infusion (median age, 68 years [46-75]). In the infused cohort, the MRD negativity rate at ...

(RTTNews) - BioCardia, Inc. (BCDA), a clinical-stage biotechnology company specializing in cellular therapies for cardiovascular disease, on Thursday announced that the first patient has been enrolled ...